APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy
Fares Al-Ejeh, Jocelyn M. Darby, Chris Tsopelas et al. · 2009
Read APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy by Fares Al-Ejeh, Jocelyn M. Darby, Chris Tsopelas et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004558.txt.
Description
An antibody test can show a tumor dying in response to chemotherapy, report Fares Al-Ejeh, Jocelyn Darby, Chris Tsopelas, and co-authors in PLOS ONE in 2009. Cancer therapy aims to kill malignant cells. Directly measuring tumor cell death in the body would be a valuable part of monitoring whether a treatment is working.
The team had developed an antibody, called APOMAB, that binds a target named La, exposed on dying cells. Here they show it detects the apoptotic tumor response to life-prolonging, DNA-damaging chemotherapy. In plain terms, a scan could reveal whether a tumor is dying weeks before it shrinks. Knowing early whether a drug works lets doctors switch failing treatments sooner and spare patients useless side effects.
Catalog record
| CREATOR | Fares Al-Ejeh, Jocelyn M. Darby, Chris Tsopelas et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004558